D. Smith

发表

p53 protein overexpression and response to biomodulated 5-fluorouracil chemotherapy in patients with advanced colorectal cancer.

A. Kinsella, M. Pickard, M. Brett, 1996, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Cetuximab in combination with irinotecan/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFIRI) in second and third-line treatment of metastatic colorectal cancer (mCRC): Safety and efficacy analysis.

D. Smith, Y. Bécouarn, J. Blanc, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The tumor burden of metastatic colorectal cancer patients at initial diagnosis, pre- versus post-Covid-19 lockdown

M. Ychou, E. Assenat, D. Smith, 2021, medRxiv.

Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV.

S. Truant, T. de Baère, M. Ducreux, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers.

P. Philip, A. Shields, D. Smith, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial

R. Salazar, R. Riechelmann, E. Van Cutsem, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

1163P Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours (NETs): An international double-blind, placebo-controlled randomized phase II trial

A. Lièvre, C. Lepage, J. Scoazec, 2020 .

R. Salazar, R. Riechelmann, E. Van Cutsem, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Updated overall survival (OS) and progression-free survival (PFS) by blinded independent central review (BICR) of sunitinib (SU) versus placebo (PBO) for patients (Pts) with advanced unresectable pancreatic neuroendocrine tumors (NET).

E. Van Cutsem, E. Raymond, A. Vinik, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer

A. Bardelli, E. Van Cutsem, J. Tabernero, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

2184 A phase 2 study of mechanisms of acquired resistance to panitumumab (pmab) plus irinotecan (iri) for metastatic colorectal cancer (mCRC)

A. Bardelli, J. Tabernero, M. Boedigheimer, 2015 .

E. Van Cutsem, M. Amonkar, D. Smith, 2020, Annals of Oncology.

LBA46 Bevacizumab (B) plus FOLFIRI after failure of platinum-etoposide in patients (pts) with advanced neuroendocrine carcinoma (NEC): The PRODIGE 41-BEVANEC randomized phase II study

I. Sobhani, A. Lièvre, C. Lepage, 2022, Annals of Oncology.

LBA41 Nivolumab (nivo) ± ipilimumab (ipi) in pre-treated patients with advanced, refractory pulmonary or gastroenteropancreatic poorly differentiated neuroendocrine tumors (NECs) (GCO-001 NIPINEC)

N. Girard, C. Lepage, J. Mazières, 2021, Annals of Oncology.

Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials.

P. Couzigou, M. Ducreux, C. Borel, 2018, European journal of cancer.